Good Manufacturing Practice– tag –
-
VIVEbiotech Reaches 15 In Vivo Lentiviral Vector Programs, Fortifying Gene Therapy Manufacturing Leadership
BioPharma BoardRoom スペイン Overview VIVEbiotech has significantly advanced its position in gene therapy manufacturing by adding its 15th in vivo lentiviral vector (LVV) therapeutic program. This milestone underscores the company's robu... -
Aurobindo Pharma Inaugurates ₹10 Billion (USD 120M) TheraNym Biologics CDMO Plant in India, Expanding Capacity by 25,000L
Sahi India Overview Aurobindo Pharma announced the inauguration of its state-of-the-art ₹10 billion (approx. USD 120 million) TheraNym biologics CDMO facility in Hyderabad, India. This plant adds 25,000 liters of mammalian cell culture c... -
CordenPharma Announces Multi-Million Dollar Expansion of Oligonucleotide Manufacturing to Meet Soaring Demand for Nucleic Acid-Based Medicines
Pharmaceutical Technology Europe Overview CordenPharma announced a multi-million dollar investment to significantly expand its oligonucleotide manufacturing capacity across its global network. This strategic expansion aims to meet the in... -
WuXi Biologics Completes and Prepares for Operation of New Antibody-Drug Conjugate (ADC) Manufacturing Facility
WuXi Biologics Press Release China Overview WuXi Biologics announced the successful completion and readiness for operation of its new integrated Antibody-Drug Conjugate (ADC) manufacturing facility. This expansion significantly enhances ... -
Samsung Biologics Secures Multi-Year mRNA Vaccine CDMO Partnership with Major Pharma, Leading Market Expansion
Business Korea South Korea Overview Samsung Biologics has reportedly secured a multi-year contract for large-scale mRNA vaccine manufacturing with a global pharmaceutical company. This new partnership further solidifies Samsung Biologics... -
Lonza Significantly Expands Biologics Manufacturing Capacity by Over 200,000 Liters with New Swiss Facility
Lonza Press Release Switzerland Overview Lonza announced the operational launch of a state-of-the-art new facility in Visp, Switzerland, significantly expanding its biopharmaceutical manufacturing capabilities. This expansion adds over 2... -
WuXi Biologics Shanghai Drug Product Facility Achieves GMP Release, Expands Global Capacity
Contract Pharma China Overview WuXi Biologics' Drug Product Facility 15 (DP15) in Shanghai secured Good Manufacturing Practice (GMP) release in April 2026, becoming its 18th operational drug product facility globally. This state-of-the-a...
12